Improving COVID-19 vaccine uptake in Black and Latinx patients with rheumatologic diseases
Official title: Improving COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Groups With Rheumatic Diseases
Run by University of Alabama at Birmingham · NCT06469788 · Data updated 2026-11-12
This study is testing a new approach to help Black and Latinx patients with autoimmune diseases get updated COVID-19 vaccines by providing them with helpful information and support.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1170 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 4 sites (Birmingham, Alabama and 3 other locations) |
| Status | Recruiting |
| Started | December 18, 2024 |
| Main results expected | September 15, 2027 |
| Study ends | May 31, 2028 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT06469788 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Black or Latinx adults aged 18 and older with known autoimmune and inflammatory rheumatic diseases who have not yet received the updated COVID-19 vaccine.
✕Probably not a fit
Patients who do not have access to a phone or who have already received the updated COVID-19 vaccine will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate a multi-modal, patient-directed behavioral intervention designed to enhance the uptake of updated COVID-19 vaccines among Black and Latinx individuals with autoimmune and inflammatory rheumatic diseases. The intervention includes patient narratives, educational videos, and brochures that address vaccine information and the importance of oral health. By focusing on these populations, the study seeks to reduce health disparities and improve vaccination rates in communities that have historically faced barriers to healthcare access. Participants will be randomly assigned to receive the intervention or standard care to assess its effectiveness.
Why it matters
Potential benefit: If successful, this intervention could significantly increase COVID-19 vaccination rates among high-risk populations, leading to better health outcomes.
How similar studies have gone: Other studies have shown success in using patient narratives and educational interventions to improve health outcomes in minority populations, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (18+ years) with known AIRD * Black race and/or Latinx ethnicity * Individuals who have not obtained the updated COVID-19 vaccine series (self-report) Exclusion Criteria: -Lack of access to phone
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting -
Northwestern University
Evanston, Illinois, United States Recruiting -
Brigham Women's Hospital
Boston, Massachusetts, United States Recruiting -
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Maria I Danila, MD, MSc, MSPH — University of Alabama at Birmingham
- Study coordinator: Mary A Wilkenson, Clinical Research Coordinator, BS
- Email: mawilkenson@uabmc.edu
- Phone: 205-996-7875
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Study on how diet affects autoimmune diseases in rheumatology patients
This study looks at how changing to a healthier diet, like the Mediterranean diet, might help people with autoimmune diseases feel better and manage their symptoms.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.